Professor of Medicine, Brigham and Women's Hospital
Internal Medicine
Dr. Daniel R. Kuritzkes, MD
|
|
Give Review
Daniel Kuritzkes practices Internal Medicine. He attended Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1 in research and 12 in primary care medicine Daniel Kuritzkes is a published doctor and has 101 publications published. The lastest was: 'Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.' He accepts all Medicare patients.
Publications
- Elevations in markers of microbial translocation and CCL2 in the aging HIV-1 infected population.
- Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.
- Comparison of the Metabolic Effects of Ritonavir boosted Darunavir or Atazanavir versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
- Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Î32.
- Emerging Technologies for Point-of-Care Management of HIV Infection.
- Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.
- Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion.
- Altered viral fitness and drug susceptibility in human inmmunodeficiency virus type 1 (HIV-1) carrying mutations that confer resistance to non-nucleoside reverse trans...
- Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viremia.
- Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.
- Early warning indicators for first-line virologic failure independent of adherence measures in a South african urban clinic.
- Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.
- Challenges in clinical trial design for HIV-1 cure research.
- Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study.
- Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248.
- Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.
- Nanoplasmonic Quantitative Detection of Intact Viruses from Unprocessed Whole Blood.
- Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.
- Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
- Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate.
- Clinical Implications of HIV-1 Minority Variants.
- Resistance in Pediatric Patients Experiencing Virologic Failure with First- and Second-Line Antiretroviral Therapy.
- HIV-1 entry inhibitors: recent development and clinical use.
- Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL.
- Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia.
- Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C.
- The Future of HIV Treatment.
- Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
- Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial.
- Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa.
- Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small Molecule CCR5 Antagonists.
- Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
- Drug Resistance in HIV-1.
- HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
- HAART for HIV-1 Infection: Zeroing In on When to Start: Comment on "Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconvert...
- Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency vi...
- Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy.
- Drug Resistance and Viral Tropism in HIV-1 Subtype C-Infected Patients in KwaZulu-Natal, South Africa: Implications for Future Treatment Options.
- Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals.
- Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
- Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana.
- Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.
- Genotypic tests for determining coreceptor usage of HIV-1.
- SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses.
- Enumeration of CD4 T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients.
- Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
- Update of the drug resistance mutations in HIV-1: December 2010.
- Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.
- Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness.
- Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
- Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.
- Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
- The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential.
- Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load.
- Update of the drug resistance mutations in HIV-1: December 2009.
- Tropism testing in the clinical management of HIV-1 infection.
- Report from the XVIII International HIV Drug Resistance Workshop.
- Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
- Interleukin-2: trials and tribulations.
- Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
- HIV-1 entry inhibitors: an overview.
- A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
- Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency vi...
- In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
- Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune par...
- Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment.
- Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
- Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
- Update of the Drug Resistance Mutations in HIV-1.
- Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
- In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
- Report from the XVII International HIV Drug Resistance Workshop.
- Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
- Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
- Update of the drug resistance mutations in HIV-1: Spring 2008.
- Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected sub...
- HIV-1 subtype as a determinant of disease progression.
- Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
- Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.
- HIV resistance: frequency, testing, mechanisms.
- Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinica...
- A comparison of three initial antiretroviral AIDS regimens.
- Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
- Report from the XVI International HIV Drug Resistance Workshop.
- TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
- Update of the drug resistance mutations in HIV-1: 2007.
- Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
- HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
- Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
- Chemokine antagonists as therapeutics: focus on HIV-1.
- Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.
- A plea for justice for jailed medical workers.
- Drug development strategies for salvage therapy: conflicts and solutions.
- Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.
- An update on HIV-1 antiretroviral resistance.
- Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
- Report from the XV International HIV Drug Resistance Workshop.
- Update of the drug resistance mutations in HIV-1: Fall 2006.
- Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
- Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
Schools
Harvard Medical School
Massachusetts General Hospital
Harvard Med College
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Education
-
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital -
Boston Children's Hospital -
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114917416 |
| Last Name Of The Provider | KURITZKES |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Elizabeth G. Rhee, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alyssa R. Letourneau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura K. Certain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James H. Maguire, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rupal S. Bhatt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca Eskin Berger, MD |
|
|
Dr. Thomas D. Sequist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert R. Korom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paige Comstock, MD |
|
|
Dr. Sarah M. Nicolai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anupama S. Gangavati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yinan Lan, MD |
|
|
Dr. Jennifer R. Siegel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hye M. Yang, MD |
|
|
Dr. Miriam R. Haverkamp, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Francis P. Magro, MD
This Doctor is OpenDoctor Recommended.
|